Idelalisib D5 is the penta-deuterated form of Idelalisib (CAL101, GS1101; CAL-101, GS-1101; Zydelig), which is an approved anticancer drug acting as a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays. Idelalisib is used for the treatment of relapsed chronic lymphocytic leukemia (CLL),
follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma
(SLL).
纯度:≥98%
CAS:1830330-31-8